BALCAO · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Viskase Holdings, Inc. VISK
17 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
—
Revenue, FY2025 · full 17-year series below
Revenue $M
Net income $M
FY2024 · Revenue 0.0 · Net income 0.8
Compound annual growth
−66.7%
−34.0%
−50.8%
−39.7%
−58.2%
−40.4%
−28.7%
−15.6%
3 yrs
5 yrs
10 yrs
15 yrs
Revenue compounded at −34.0% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2024 · Operating -5103.8% · Net 2992.3%
ROE
FY2025 · ROE -1411.6%
Each USD of equity lost 1412 cents this year.
The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | · | 0.0 | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.1 |
| EBITDA $B | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | −0.0 | 0.0 | · |
| Income tax $B | 0.0 | 0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 |
| Net income $B | −0.0 | 0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 | 0.2 | 0.0 |
| Free cash flow $B | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 |
| EPS, diluted $ | −0.07 | 0.01 | 0.00 | −0.02 | −0.03 | −0.03 | −0.02 | 0.13 | 0.12 | −0.03 | 0.49 | 0.65 | 0.38 | −0.06 | −0.40 | 3.03 | 0.02 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | 0.15 | 0.85 | 0.00 | 2.05 | 2.00 | 2.00 | 0.00 | · |
| Payout % | −37 | 164 | 93 | · | −0 | −0 | −813 | 0 | 122 | −589 | 174 | 15 | 495 | −3139 | −0 | · | · |
| ROE % | −1411.6 | · | · | −4.5 | −7.7 | −19.5 | −9.3 | 48.5 | 55.9 | −7.9 | 90.7 | 165.2 | 43.9 | −2.0 | −7.8 | 92.0 | 1.3 |
| Shares out B | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.05 | 0.06 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 64 reconciliationsAUDITED
Reconciled in 17 of 19 fiscal years. 12 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009